J

ust under a year ago, Veritas Genetics announced it would be launching the first whole genome sequencing test with a price tag under $1,000. Now, the company is bringing on board a new vice president of clinical affairs to help lower the cost of that sequencing and improve the process of interpreting the results.

Birgit Funke has worked extensively on the genetic underpinnings of inherited heart diseases, including cardiomyopathies, and has also written about the racial disparities in genetic testing and research. As of February 1, Funke has split her time between the Danvers, Mass.-based spinoff of the non-profit Personal Genome Project and her work as an associate professor at Harvard Medical School and a researcher at Partners Personalized Medicine’s Laboratory of Molecular Medicine.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy